Ligand validation:6XCG

V01: N-cyclopropyl-3-oxo-N-({4-[(pyrimidin-4-yl)carbamoyl]phenyl}methyl)-3,4-dihydro-2H-1,4-benzoxazine-7-carboxamide

V01 is a Ligand Of Interest in 6XCG designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6XCG_V01_B_401	73%	72%	0.094	0.921	0.54	0.54	-	1	0	0	100%	1
6XCG_V01_C_401	72%	80%	0.104	0.929	0.44	0.39	-	-	0	0	100%	1
6XCG_V01_A_401	67%	75%	0.101	0.908	0.35	0.62	-	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.